
Vesalius Therapeutics: Innovating drug development to combat major human illnesses.
Vesalius Therapeutics, founded by Flagship Pioneering, is dedicated to revolutionizing the treatment of diseases responsible for 90% of human illness. The company’s core mission is to fundamentally reconceptualize drug development for common diseases, aiming to improve patient outcomes through innovative therapeutic approaches. Vesalius Therapeutics focuses on creating groundbreaking treatments that address significant unmet medical needs, leveraging cutting-edge research and development methodologies.
Notable affiliates include Flagship Pioneering, a renowned venture capital firm known for nurturing transformative biotech companies. Vesalius Therapeutics has made significant strides in its field, marked by pioneering research and promising clinical advancements. The company's impact lies in its potential to redefine disease treatment paradigms, offering hope for more effective therapies for widespread health conditions.

ProFound Therapeutics
profoundtx.com

Ampersand Biomedicines
ampersand.bio

Valo Health
valohealth.com

Ventus Therapeutics

Exalys Therapeutics

Vasa Therapeutics

Valerion Therapeutics

Curie.Bio
curie.bio

Marlinspike Therapeutics

Thetis Pharmaceuticals
thetispharma.com

Celsius Therapeutics
celsiustx.com

Chase Therapeutics

Eikon Therapeutics
eikontx.com

Triplet Therapeutics
triplettx.com

Variant Bio
variantbio.com
Companies similar to Vesalius Therapeutics include ProFound Therapeutics, Ampersand Biomedicines, Valo Health and Ventus Therapeutics.
Vesalius Therapeutics was founded in 2019.
Vesalius Therapeutics' headquarters is located in Cambridge, MA, US.
Vesalius Therapeutics' most recent funding round was for $75M (USD) in March 2022.
As of Mar 2, 2022, Vesalius Therapeutics has raised a total of $75M (USD).
Vesalius Therapeutics has 35 employees as of Feb 4, 2024.